US 9,809,577 B2
Biaryl inhibitors of Bruton's tyrosine kinase
Brian T. Hopkins, Newton, MA (US); Bin Ma, Arlington, MA (US); Timothy Raymond Chan, Newton, MA (US); Lihong Sun, Lexington, MA (US); Lei Zhang, Westford, MA (US); Gnanasambandam Kumaravel, Westford, MA (US); Joseph P. Lyssikatos, Cambridge, MA (US); Kevin Koch, Cambridge, MA (US); and Hua Miao, Newton, MA (US)
Assigned to Biogen MA Inc., Cambridge, MA (US)
Appl. No. 15/103,749
Filed by BIOGEN MA INC., Cambridge, MA (US)
PCT Filed Dec. 11, 2014, PCT No. PCT/US2014/069853
§ 371(c)(1), (2) Date Jun. 10, 2016,
PCT Pub. No. WO2015/089337, PCT Pub. Date Jun. 18, 2015.
Claims priority of provisional application 61/914,886, filed on Dec. 11, 2013.
Prior Publication US 2016/0311802 A1, Oct. 27, 2016
Int. Cl. C07D 403/12 (2006.01); C07D 417/14 (2006.01); C07D 495/04 (2006.01); C07D 409/14 (2006.01); C07D 401/14 (2006.01); C07D 513/04 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 487/04 (2006.01)
CPC C07D 403/12 (2013.01) [C07D 401/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 487/04 (2013.01); C07D 495/04 (2013.01); C07D 513/04 (2013.01)] 2 Claims
 
1. A compound of formula I-21:

OG Complex Work Unit Drawing
or a pharmaceutically acceptable salt thereof.